Report Detail
COVID-19 Impact on Global Neuromuscular Blocking Agent (NMBA) Market Insights, Forecast to 2026
- RnM4069720 |
- 19 June, 2020 |
- Global |
- 110 Pages |
- QYResearch |
- Pharma & Healthcare
Neuromuscular Blocking Agent (NMBA) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Neuromuscular Blocking Agent (NMBA) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Neuromuscular Blocking Agent (NMBA) market is segmented into
Depolarizing
Non-depolarizing
Segment by Application, the Neuromuscular Blocking Agent (NMBA) market is segmented into
Hospital
Clinic
Pharmacy
Others
Regional and Country-level Analysis
The Neuromuscular Blocking Agent (NMBA) market is analysed and market size information is provided by regions (countries).
The key regions covered in the Neuromuscular Blocking Agent (NMBA) market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Neuromuscular Blocking Agent (NMBA) Market Share Analysis
Neuromuscular Blocking Agent (NMBA) market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Neuromuscular Blocking Agent (NMBA) business, the date to enter into the Neuromuscular Blocking Agent (NMBA) market, Neuromuscular Blocking Agent (NMBA) product introduction, recent developments, etc.
The major vendors covered:
AbbVie
GlaxoSmithKline
Pfizer
Hengrui Pharmaceutical
Abbott Laboratories
Fresenius Kabi
Sandoz
Somerset Therapeutics
Guike Pharmaceutical
Shanghai Pharmaceuticals
Themis Medicare
Nanjing King-Friend
1 Study Coverage
- 1.1 Neuromuscular Blocking Agent (NMBA) Product Introduction
- 1.2 Market Segments
- 1.3 Key Neuromuscular Blocking Agent (NMBA) Manufacturers Covered: Ranking by Revenue
- 1.4 Market by Type
- 1.4.1 Global Neuromuscular Blocking Agent (NMBA) Market Size Growth Rate by Type
- 1.4.2 Depolarizing
- 1.4.3 Non-depolarizing
- 1.5 Market by Application
- 1.5.1 Global Neuromuscular Blocking Agent (NMBA) Market Size Growth Rate by Application
- 1.5.2 Hospital
- 1.5.3 Clinic
- 1.5.4 Pharmacy
- 1.5.5 Others
- 1.6 Coronavirus Disease 2019 (Covid-19): Neuromuscular Blocking Agent (NMBA) Industry Impact
- 1.6.1 How the Covid-19 is Affecting the Neuromuscular Blocking Agent (NMBA) Industry
- 1.6.1.1 Neuromuscular Blocking Agent (NMBA) Business Impact Assessment - Covid-19
- 1.6.1.2 Supply Chain Challenges
- 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
- 1.6.2 Market Trends and Neuromuscular Blocking Agent (NMBA) Potential Opportunities in the COVID-19 Landscape
- 1.6.3 Measures / Proposal against Covid-19
- 1.6.3.1 Government Measures to Combat Covid-19 Impact
- 1.6.3.2 Proposal for Neuromuscular Blocking Agent (NMBA) Players to Combat Covid-19 Impact
- 1.6.1 How the Covid-19 is Affecting the Neuromuscular Blocking Agent (NMBA) Industry
- 1.7 Study Objectives
- 1.8 Years Considered
2 Executive Summary
- 2.1 Global Neuromuscular Blocking Agent (NMBA) Market Size Estimates and Forecasts
- 2.1.1 Global Neuromuscular Blocking Agent (NMBA) Revenue 2015-2026
- 2.1.2 Global Neuromuscular Blocking Agent (NMBA) Sales 2015-2026
- 2.2 Neuromuscular Blocking Agent (NMBA) Market Size by Region: 2020 Versus 2026
- 2.2.1 Global Neuromuscular Blocking Agent (NMBA) Retrospective Market Scenario in Sales by Region: 2015-2020
- 2.2.2 Global Neuromuscular Blocking Agent (NMBA) Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Neuromuscular Blocking Agent (NMBA) Competitor Landscape by Players
- 3.1 Neuromuscular Blocking Agent (NMBA) Sales by Manufacturers
- 3.1.1 Neuromuscular Blocking Agent (NMBA) Sales by Manufacturers (2015-2020)
- 3.1.2 Neuromuscular Blocking Agent (NMBA) Sales Market Share by Manufacturers (2015-2020)
- 3.2 Neuromuscular Blocking Agent (NMBA) Revenue by Manufacturers
- 3.2.1 Neuromuscular Blocking Agent (NMBA) Revenue by Manufacturers (2015-2020)
- 3.2.2 Neuromuscular Blocking Agent (NMBA) Revenue Share by Manufacturers (2015-2020)
- 3.2.3 Global Neuromuscular Blocking Agent (NMBA) Market Concentration Ratio (CR5 and HHI) (2015-2020)
- 3.2.4 Global Top 10 and Top 5 Companies by Neuromuscular Blocking Agent (NMBA) Revenue in 2019
- 3.2.5 Global Neuromuscular Blocking Agent (NMBA) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.3 Neuromuscular Blocking Agent (NMBA) Price by Manufacturers
- 3.4 Neuromuscular Blocking Agent (NMBA) Manufacturing Base Distribution, Product Types
- 3.4.1 Neuromuscular Blocking Agent (NMBA) Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Neuromuscular Blocking Agent (NMBA) Product Type
- 3.4.3 Date of International Manufacturers Enter into Neuromuscular Blocking Agent (NMBA) Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
- 4.1 Global Neuromuscular Blocking Agent (NMBA) Market Size by Type (2015-2020)
- 4.1.1 Global Neuromuscular Blocking Agent (NMBA) Sales by Type (2015-2020)
- 4.1.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2015-2020)
- 4.1.3 Neuromuscular Blocking Agent (NMBA) Average Selling Price (ASP) by Type (2015-2026)
- 4.2 Global Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Type (2021-2026)
- 4.2.1 Global Neuromuscular Blocking Agent (NMBA) Sales Forecast by Type (2021-2026)
- 4.2.2 Global Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Type (2021-2026)
- 4.2.3 Neuromuscular Blocking Agent (NMBA) Average Selling Price (ASP) Forecast by Type (2021-2026)
- 4.3 Global Neuromuscular Blocking Agent (NMBA) Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Breakdown Data by Application (2015-2026)
- 5.1 Global Neuromuscular Blocking Agent (NMBA) Market Size by Application (2015-2020)
- 5.1.1 Global Neuromuscular Blocking Agent (NMBA) Sales by Application (2015-2020)
- 5.1.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Application (2015-2020)
- 5.1.3 Neuromuscular Blocking Agent (NMBA) Price by Application (2015-2020)
- 5.2 Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Application (2021-2026)
- 5.2.1 Global Neuromuscular Blocking Agent (NMBA) Sales Forecast by Application (2021-2026)
- 5.2.2 Global Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Application (2021-2026)
- 5.2.3 Global Neuromuscular Blocking Agent (NMBA) Price Forecast by Application (2021-2026)
6 North America
- 6.1 North America Neuromuscular Blocking Agent (NMBA) by Country
- 6.1.1 North America Neuromuscular Blocking Agent (NMBA) Sales by Country
- 6.1.2 North America Neuromuscular Blocking Agent (NMBA) Revenue by Country
- 6.1.3 U.S.
- 6.1.4 Canada
- 6.2 North America Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Type
- 6.3 North America Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Application
7 Europe
- 7.1 Europe Neuromuscular Blocking Agent (NMBA) by Country
- 7.1.1 Europe Neuromuscular Blocking Agent (NMBA) Sales by Country
- 7.1.2 Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 U.K.
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Type
- 7.3 Europe Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Application
8 Asia Pacific
- 8.1 Asia Pacific Neuromuscular Blocking Agent (NMBA) by Region
- 8.1.1 Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales by Region
- 8.1.2 Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Region
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 South Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Taiwan
- 8.1.9 Indonesia
- 8.1.10 Thailand
- 8.1.11 Malaysia
- 8.1.12 Philippines
- 8.1.13 Vietnam
- 8.2 Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Type
- 8.3 Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Application
9 Latin America
- 9.1 Latin America Neuromuscular Blocking Agent (NMBA) by Country
- 9.1.1 Latin America Neuromuscular Blocking Agent (NMBA) Sales by Country
- 9.1.2 Latin America Neuromuscular Blocking Agent (NMBA) Revenue by Country
- 9.1.3 Mexico
- 9.1.4 Brazil
- 9.1.5 Argentina
- 9.2 Central & South America Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Type
- 9.3 Central & South America Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Application
10 Middle East and Africa
- 10.1 Middle East and Africa Neuromuscular Blocking Agent (NMBA) by Country
- 10.1.1 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales by Country
- 10.1.2 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue by Country
- 10.1.3 Turkey
- 10.1.4 Saudi Arabia
- 10.1.5 U.A.E
- 10.2 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Type
- 10.3 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Application
11 Company Profiles
- 11.1 AbbVie
- 11.1.1 AbbVie Corporation Information
- 11.1.2 AbbVie Description, Business Overview and Total Revenue
- 11.1.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
- 11.1.4 AbbVie Neuromuscular Blocking Agent (NMBA) Products Offered
- 11.1.5 AbbVie Recent Development
- 11.2 GlaxoSmithKline
- 11.2.1 GlaxoSmithKline Corporation Information
- 11.2.2 GlaxoSmithKline Description, Business Overview and Total Revenue
- 11.2.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
- 11.2.4 GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Products Offered
- 11.2.5 GlaxoSmithKline Recent Development
- 11.3 Pfizer
- 11.3.1 Pfizer Corporation Information
- 11.3.2 Pfizer Description, Business Overview and Total Revenue
- 11.3.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
- 11.3.4 Pfizer Neuromuscular Blocking Agent (NMBA) Products Offered
- 11.3.5 Pfizer Recent Development
- 11.4 Hengrui Pharmaceutical
- 11.4.1 Hengrui Pharmaceutical Corporation Information
- 11.4.2 Hengrui Pharmaceutical Description, Business Overview and Total Revenue
- 11.4.3 Hengrui Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
- 11.4.4 Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Products Offered
- 11.4.5 Hengrui Pharmaceutical Recent Development
- 11.5 Abbott Laboratories
- 11.5.1 Abbott Laboratories Corporation Information
- 11.5.2 Abbott Laboratories Description, Business Overview and Total Revenue
- 11.5.3 Abbott Laboratories Sales, Revenue and Gross Margin (2015-2020)
- 11.5.4 Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Products Offered
- 11.5.5 Abbott Laboratories Recent Development
- 11.6 Fresenius Kabi
- 11.6.1 Fresenius Kabi Corporation Information
- 11.6.2 Fresenius Kabi Description, Business Overview and Total Revenue
- 11.6.3 Fresenius Kabi Sales, Revenue and Gross Margin (2015-2020)
- 11.6.4 Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Products Offered
- 11.6.5 Fresenius Kabi Recent Development
- 11.7 Sandoz
- 11.7.1 Sandoz Corporation Information
- 11.7.2 Sandoz Description, Business Overview and Total Revenue
- 11.7.3 Sandoz Sales, Revenue and Gross Margin (2015-2020)
- 11.7.4 Sandoz Neuromuscular Blocking Agent (NMBA) Products Offered
- 11.7.5 Sandoz Recent Development
- 11.8 Somerset Therapeutics
- 11.8.1 Somerset Therapeutics Corporation Information
- 11.8.2 Somerset Therapeutics Description, Business Overview and Total Revenue
- 11.8.3 Somerset Therapeutics Sales, Revenue and Gross Margin (2015-2020)
- 11.8.4 Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Products Offered
- 11.8.5 Somerset Therapeutics Recent Development
- 11.9 Guike Pharmaceutical
- 11.9.1 Guike Pharmaceutical Corporation Information
- 11.9.2 Guike Pharmaceutical Description, Business Overview and Total Revenue
- 11.9.3 Guike Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
- 11.9.4 Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Products Offered
- 11.9.5 Guike Pharmaceutical Recent Development
- 11.10 Shanghai Pharmaceuticals
- 11.10.1 Shanghai Pharmaceuticals Corporation Information
- 11.10.2 Shanghai Pharmaceuticals Description, Business Overview and Total Revenue
- 11.10.3 Shanghai Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
- 11.10.4 Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Products Offered
- 11.10.5 Shanghai Pharmaceuticals Recent Development
- 11.1 AbbVie
- 11.1.1 AbbVie Corporation Information
- 11.1.2 AbbVie Description, Business Overview and Total Revenue
- 11.1.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
- 11.1.4 AbbVie Neuromuscular Blocking Agent (NMBA) Products Offered
- 11.1.5 AbbVie Recent Development
- 11.12 Nanjing King-Friend
- 11.12.1 Nanjing King-Friend Corporation Information
- 11.12.2 Nanjing King-Friend Description, Business Overview and Total Revenue
- 11.12.3 Nanjing King-Friend Sales, Revenue and Gross Margin (2015-2020)
- 11.12.4 Nanjing King-Friend Products Offered
- 11.12.5 Nanjing King-Friend Recent Development
12 Future Forecast by Regions (Countries) (2021-2026)
- 12.1 Neuromuscular Blocking Agent (NMBA) Market Estimates and Projections by Region
- 12.1.1 Global Neuromuscular Blocking Agent (NMBA) Sales Forecast by Regions 2021-2026
- 12.1.2 Global Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Regions 2021-2026
- 12.2 North America Neuromuscular Blocking Agent (NMBA) Market Size Forecast (2021-2026)
- 12.2.1 North America: Neuromuscular Blocking Agent (NMBA) Sales Forecast (2021-2026)
- 12.2.2 North America: Neuromuscular Blocking Agent (NMBA) Revenue Forecast (2021-2026)
- 12.2.3 North America: Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Country (2021-2026)
- 12.3 Europe Neuromuscular Blocking Agent (NMBA) Market Size Forecast (2021-2026)
- 12.3.1 Europe: Neuromuscular Blocking Agent (NMBA) Sales Forecast (2021-2026)
- 12.3.2 Europe: Neuromuscular Blocking Agent (NMBA) Revenue Forecast (2021-2026)
- 12.3.3 Europe: Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Country (2021-2026)
- 12.4 Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Size Forecast (2021-2026)
- 12.4.1 Asia Pacific: Neuromuscular Blocking Agent (NMBA) Sales Forecast (2021-2026)
- 12.4.2 Asia Pacific: Neuromuscular Blocking Agent (NMBA) Revenue Forecast (2021-2026)
- 12.4.3 Asia Pacific: Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Region (2021-2026)
- 12.5 Latin America Neuromuscular Blocking Agent (NMBA) Market Size Forecast (2021-2026)
- 12.5.1 Latin America: Neuromuscular Blocking Agent (NMBA) Sales Forecast (2021-2026)
- 12.5.2 Latin America: Neuromuscular Blocking Agent (NMBA) Revenue Forecast (2021-2026)
- 12.5.3 Latin America: Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Country (2021-2026)
- 12.6 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Size Forecast (2021-2026)
- 12.6.1 Middle East and Africa: Neuromuscular Blocking Agent (NMBA) Sales Forecast (2021-2026)
- 12.6.2 Middle East and Africa: Neuromuscular Blocking Agent (NMBA) Revenue Forecast (2021-2026)
- 12.6.3 Middle East and Africa: Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Porter’s Five Forces Analysis
- 13.5 Primary Interviews with Key Neuromuscular Blocking Agent (NMBA) Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Neuromuscular Blocking Agent (NMBA) Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
Summary:
Get latest Market Research Reports on COVID-19 Impact on Global Neuromuscular Blocking Agent (NMBA). Industry analysis & Market Report on COVID-19 Impact on Global Neuromuscular Blocking Agent (NMBA) is a syndicated market report, published as COVID-19 Impact on Global Neuromuscular Blocking Agent (NMBA) Market Insights, Forecast to 2026. It is complete Research Study and Industry Analysis of COVID-19 Impact on Global Neuromuscular Blocking Agent (NMBA) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
